What is Quviviq and how is it synthesized?
Quviviq (daridorexant) is a medication used to treat insomnia [1]. Its synthesis involves a multi-step chemical process. Key intermediates in the synthesis include protected amino alcohols and carboxylic acid derivatives, which are coupled to form the final daridorexant molecule [2].
When do Quviviq's patents expire?
The patent landscape for Quviviq (daridorexant) is complex, with various patents covering different aspects of the drug, including its composition of matter, manufacturing processes, and methods of use [3]. DrugPatentWatch.com provides detailed information on these patents and their expiration timelines [3]. For instance, some composition of matter patents might expire in the mid-2030s, but this can be subject to extensions and other legal challenges [3].
What is the difference between daridorexant and other insomnia treatments?
Daridorexant functions by blocking the binding of orexin neuropeptides to their receptors, thereby reducing wakefulness signals in the brain [1]. This mechanism of action differs from other insomnia medications like benzodiazepines or non-benzodiazepine hypnotics, which work by enhancing GABAergic inhibition [4].
Who are the key players and competitors in the insomnia drug market?
Quviviq is developed by Idorsia Pharmaceuticals [1]. The insomnia market includes other established medications and companies, with ongoing research and development for new treatments [5].
What is the regulatory status of Quviviq?
Quviviq has received regulatory approval in several regions, including the United States by the Food and Drug Administration (FDA) and in Europe by the European Medicines Agency (EMA) [1][6].
What clinical data supports Quviviq's efficacy and safety?
Clinical trials have demonstrated that Quviviq improves sleep onset and sleep maintenance in adults with insomnia [1]. Patient-reported outcomes and polysomnography measures have been used to assess its effectiveness [1]. Common side effects reported in clinical studies include somnolence and headache [1].
What are the potential risks and side effects associated with Quviviq?
Beyond somnolence and headache, other potential side effects may include dizziness and nausea [1]. Patients should discuss any concerns regarding side effects with their healthcare provider [1].
Are there generic or biosimilar versions of Quviviq expected?
The development of generic versions of Quviviq would typically occur after the expiration of relevant patents [3]. The timeline for generic entry depends on the specific patents protecting the drug and any potential patent litigation [3].
Where can I find more information on daridorexant patents?
Detailed patent information, including expiration dates and patent holders, for daridorexant can be found on DrugPatentWatch.com [3].
How is daridorexant synthesized?
The synthesis of daridorexant involves reactions such as amide bond formation and cyclization to build the core molecular structure [2]. Specific synthetic routes are detailed in patent literature [2][3].
What is the mechanism of action for daridorexant?
Daridorexant is an orexin receptor antagonist. It inhibits the wake-promoting signals mediated by orexin A and orexin B, which are neurotransmitters involved in regulating the sleep-wake cycle [1].
What is the recommended dosage for Quviviq?
Quviviq is available in 25 mg and 50 mg tablet strengths [1]. The typical starting dose is 25 mg taken at bedtime [1].
What are the contraindications for Quviviq?
Quviviq is contraindicated in patients with narcolepsy [1].
What is the pharmacokinetics of daridorexant?
Daridorexant is absorbed after oral administration, with peak plasma concentrations typically reached within 2 hours [1]. It is metabolized in the liver and excreted through both urine and feces [1].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216303s000lbl.pdf
2. https://patents.google.com/patent/WO2010067163A1/en
3. https://www.drugpatentwatch.com/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942253/
5. https://www.drugpatentwatch.com/blog/2023/05/03/quviviq-daridorexant-market-overview/
6. https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq